Compare NRXP & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRXP | VRCA |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.2M | 87.5M |
| IPO Year | N/A | 2018 |
| Metric | NRXP | VRCA |
|---|---|---|
| Price | $1.79 | $5.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $30.67 | $17.00 |
| AVG Volume (30 Days) | ★ 516.9K | 130.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $372.93 |
| Revenue Next Year | $847.91 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.58 | $0.39 |
| 52 Week High | $3.84 | $9.82 |
| Indicator | NRXP | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 42.16 | 33.64 |
| Support Level | $1.65 | $5.34 |
| Resistance Level | $2.79 | $6.44 |
| Average True Range (ATR) | 0.11 | 0.47 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 36.21 | 10.24 |
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.